Viagra safety has been empirically proven over the years of its use in men of different age groups and health history background. The medicinal agent contained in viagra discounts was initially developed to be a remedy against pulmonary heart disease (PHD), since it features a powerful vasodilatory characteristic. It is by way of dilating the walls of the blood vessels that Viagra works, causing the vessels to expand and absorb as much blood as it is needed for harder, bigger and better erections to take place at patient’s will during 4 hours.

The prevalence of hypogonadism in the older age groups is highest—higher than ini-tially suspected. Normal aging results in changes in androgen status and effect through several mechanisms, including alterations in feedback sensitivities; decline in synthetic capacity; changes in serum availability, aging, or responder cells; and interaction with other hormone and regulatory systems (e.g., dihydroepiandrosterone [DHEA], growth hormone, melatonin, and leptin;). There is significant variation in the age at which such changes become apparent as well as in the speed and degree of the changes and the systems that are affected. There is undoubtedly a significant incidence of androgen defi-ciency in older males when measured by serum levels of bio-available testosterone.

The male climacteric is referred to as andropause, androgen decline in the aging male, late-onset hypogonadism (LOH), or symptomatic LOH. Data from the MMAS suggested that each year, biochemical LOH will be present in 481,000 new cases involving US males ages 40 to 69. Similar numbers can be projected for Europe. Although the MMAS was unable to show an association between ED and a decrease in the serum levels of tes-tosterone, a direct correlation was established between ED and a serum deficit in DHEA and its sulfated form, DHEAS. It is possible in a population study to link age and serum testosterone, but the association between low DHEA and increasing age is so strong and predictable that the specific association between DHEA and ED, independent of age, is difficult to demonstrate. However, a recent study pointed to a true finding of lower DHEA in patients with ED compared to controls. A diagnosis of hypogonadism can rarely be established on the basis of history and physical examination alone.

Antihypertensive Agents Viagra online in Canada

The most frequent organic cause of ED is a disturbance of blood flow to and from the penis.

Atherosclerotic or traumatic arterial disease can decrease flow to the lacunar spaces, resulting in decreased rigidity and an increased time to full erection. In theory, any agent that decreases systemic pressure, subsequently altering the hemodynamics of pelvic blood flow, can potentiate ED. Thus, it is not surprising that sexual dysfunction has been associated with nearly all available classes of hypertensive medication. These agents have been strongly correlated with new onset ED.

While hypertension alone is considered a risk factor for ED, a population­ based prospective study of over 1,000 randomly selected men in the Massachusetts Male Aging Study (MMAS), identified select antihypertensive treatments (specifically thiazide diuretics, spironolactone, b-blockers, methyldopa, and clonidine), and not the condition itself, as an independent risk factor. However, logistic regression analyses with the adjustment for comorbidities and health behaviors attenuated these associations, finding that only nonthiazide diuretics and benzodiazepines were associated with ED to statistical significance. Studies like these make it difficult to interpret the previous literature surrounding antihypertensive­induced ED.

Among the antihypertensive agents, the b-blockers have been one of the most commonly implicated classes. The prevalence of b-blocker-induced sexual dysfunction has been reported to be anywhere from 5 to 43%. ED has been reported with higher doses of propranolol as well as with other, newer b-blockers as well. The proposed pathophysiology is via decreased corporal blood flow, suppression of CNS sympathetic outflow and in the case of non-specific blockers, inhibition of b2-mediated peripheral vasodilatation leading to insufficient relaxation of the corpora.

Thiazide diuretics are some of the most commonly used antihypertensives. This class is also commonly implicated as eliciting ED. The incidence of thiazide diuretic­induced ED has been reported to be anywhere from 4 and 32%. Calcium channel blockers, angiotensin­converting enzyme inhibitors and vasodilators such as hydralazine are other antihypertensive agents linked to drug­induced ED. While the mechanism of action is not completely understood, it has been hypothesized that these drugs act directly at the corporal level (for instance, calcium channel blockers) or indirectly by reducing pelvic blood pressure, which is important in the development of penile rigidity. Buy cialis Australia – cheap ed solutions online.

Drug­induced ED is not limited to difficulties initiating and maintaining erections. Certain drugs have been reported to induce an absence of ejaculation. Some a-blockers, tamsulosin and silodosin, have been associated with this phenomenon, purportedly through relaxation of the seminal vesicles. While a-blockers have historically been used for hypertension, the practicing urologist is often more familiar with the use of this class of drugs in the treatment of benign prostatic hyperplasia (BPH). Epidemi­ ologic evidence suggests that ED and BPH are conditions that often arise together. Because preliminary clinical data suggests that the addition of an a1­blocker to a PDE­5 inhibitor can actually attenuate ED, multiple groups have investigated the effects of concomitant application of various a1­blocker and PDE­5 inhibitor combinations on human and animal cavernosal tissue as compared to each drug alone. In vitro studies on human tissue demonstrate that the combination of these two drugs exert an additive relaxant effect on cavernosal smooth muscle. In vivo models in the rat suggest that a1­blockers can actually increase NO synthesis, alter sympathetic tone and augment blood flow in penile tissue when bladder-outlet obstruction and ED are present.

Antihypertensive Medications.
The majority of antihypertensive medications have been implicated in sexual disorders. However, some substances are more likely than others to cause ED. For example, diuretics (e.g., chlorthalidone, hydrochlorothiazide, and spironolactone), central antiadrenergic agents (e.g., clonidine, methyldopa, reserpine), and guanethidine are commonly cited as causes of ED. However, β-blockers, with the exception of propranolol, are less likely to cause ED, but can cause desire disorders. Angiotensinconverting enzyme inhibitors may be least likely to cause ED. In addition, minoxidil, hydralazine, prazosin, and furosemide rarely cause sexual side effects, although hydralazine and prazosin have been associated with priapism in case reports.

Psychiatric Medications.
Psychiatric medications also commonly affect sexual function. Antidepressants (e.g., amitriptyline, amoxapine, clomipramine, desipramine, nortriptyline, protriptyline) have frequently been associated with ED and can cause a delayed or absent orgasmic response. Similar side effects have been reported with selective serotonin reuptake inhibitors, such as fluoxetine and sertraline. Antipsychotic medications (e.g., thioridazine, chlorpromazine), without exception, have the potential for disrupting sexual response. Lithium and monoaminooxidase inhibitors may impair sexual desire and erectile function. Many other prescription medications in diverse therapeutic classes are frequently cited as causing sexual dysfunctions. These include carbamazepine, digoxin, disulfiram, and ketoconazole. In addition, antihyperlipidemic agents like clofibrate and gemfibrozil have been associated with ED. The statins appear to have a lower risk. Hormonal agents, including antiandrogens, LH-RH analogs, and estrogens, also increase the risk of ED. Other drugs associated with ED include protease inhibitors, cytotoxic agents, and H2-receptor antagonists.

Psychogenic Causes of ED
Psychogenic ED frequently coexists with other sexual dysfunctions, notably hypoactive sexual desire, and with major psychiatric disorders, particularly depression and anxiety disorders. In the latter cases, a primary diagnosis may be difficult to establish, and concomitant treatment of the patient’s psychiatric disorder may be indicated as the initial step in management.

Many men with ED also have comorbid depression, and the relation between them appears to be bidirectional; the occurrence of either disorder may cause, result from, or exacerbate the other. There are five models, not mutually exclusive, that describe a possible relation between ED and depression.

1. First, ED may lead to “secondary” depression in vulnerable individuals. Studies have shown that men with ED are more likely to report depressive symptoms than are men without ED.
2. Second, ED can be symptomatic of a “primary” depressive episode. That is, men who are depressed frequently manifest symptoms of ED. Furthermore, some men with major depressive disorder develop a reversible loss of nocturnal penile tumescence, suggesting that depression can influence erectile neurophysiology .
3. Third, a common factor may be related to the development of both conditions. ED and depression frequently co-occur with other conditions, including diabetes, hypertension, cardiovascular disease, neurologic disorders (e.g., parkinsonism, multiple sclerosis), and endocrine disorders (e.g., adrenal, thyroid, gonadal). Numerous epidemiologic studies have indicated that the concurrence of depressive symptoms, particularly major depressive disorder, increased the risk of ischemic heart disease and mortality. Other data showed that depression was a significant, independent risk factor for the development of symptomatic ischemic heart disease in otherwise healthy individuals. Conversely, medical illness can precipitate depression in a predisposed individual. Significantly, ED, depression, and vascular disease share a number of risk factors, including smoking, obesity, dyslipidemia, and a sedentary lifestyle.
4. Fourth, ED can be an adverse effect of medication treatments for these conditions, including antidepressants, antihypertensives, cardiac drugs, and numerous other agents. Between 5 and 80% of patients taking antidepressants experience side effects related to sexual function. Similarly, between 10 and 50% of men taking antihypertensives experience ED while on therapy.
5. Finally, as relatively prevalent conditions, ED and depression can be coincidentally comorbid and, thus, etiologically unrelated.

The significance of psychosocial factors in the etiology of ED has been highlighted in epidemiological studies. In the MMAS, ED was significantly associated with depressive symptoms, pessimistic attitudes, or a negative outlook on life. Similarly, in the National Health and Social Life Survey, ED was significantly associated with emotional stress and a history of social coercion. These studies underline the significant effects of psychosocial factors in the etiology of ED. Female viagra pills

Generally, psychosocial determinants of ED are divided into immediate and remote causes. Immediate causes include performance anxiety (or fear of failure), lack of adequate stimulation, and relationship conflicts. Among the remote or early developmental causes, various researchers have emphasized the role of sexual trauma in childhood, sexual identity or orientation issues, unresolved partner or parental attachments, and religious or cultural taboos.

Frequently, interpersonal and relationship factors have been associated with ED. Communication difficulties, lack of intimacy or trust, and power conflicts have been emphasized as frequent concomitants of arousal difficulties in both sexes. Loss of sexual attraction has also been implicated.

An expanded classification system for psychogenic ED has been proposed by the nomenclature committee of the International Society of Impotence Research. This new classification is intended to broaden the previously limited focus of psychogenic ED and incorporates clinical features (general vs situational ED) and hypothesized etiologic mechanisms (central excitation vs inhibition) of psychogenic ED. Recent studies have strongly implicated the role of central excitatory and inhibitory mechanisms in the control of male sexual arousal. These concepts are incorporated into the proposed classification system.

In addition to the clinical subtypes of generalized vs situational, psychogenic ED can be characterized as lifelong (primary) or acquired (secondary).

Primary psychogenic ED refers to the lifelong inability to achieve successful sexual performance, whereas secondary psychogenic ED occurs after a period of satisfactory sexual performance. Primary psychogenic ED is relatively rare and usually associated with a chronic pattern of sexual or interpersonal inhibition. Psychogenic ED may also be classified as secondary to substance abuse or a major psychiatric disorder.